QURE Key Statistics, Chart & Performance
The current stock price of QURE is 27.51 USD. In the past month the price decreased by -59.46%. In the past year, price increased by 360.8%.
QURE Latest News, Press Relases and Analysis
QURE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About QURE
Company Profile
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 209 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Company Info
UNIQURE NV
Paasheuvelweg 25a
Amsterdam NOORD-HOLLAND 1105 BP NL
CEO: Matthew Kapusta
Employees: 209
Phone: 31202406000
UNIQURE NV / QURE FAQ
Can you describe the business of UNIQURE NV?
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 209 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Can you provide the latest stock price for UNIQURE NV?
The current stock price of QURE is 27.51 USD. The price decreased by -0.43% in the last trading session.
Does UNIQURE NV pay dividends?
QURE does not pay a dividend.
What is the ChartMill rating of UNIQURE NV stock?
QURE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for QURE stock?
UNIQURE NV (QURE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.41).
What is the ownership structure of UNIQURE NV (QURE)?
You can find the ownership structure of UNIQURE NV (QURE) on the Ownership tab.
What is the outstanding short interest for UNIQURE NV?
The outstanding short interest for UNIQURE NV (QURE) is 11.95% of its float.
QURE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to QURE. When comparing the yearly performance of all stocks, QURE is one of the better performing stocks in the market, outperforming 99.06% of all stocks.
QURE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to QURE. QURE has a bad profitability rating. Also its financial health evaluation is rather negative.
QURE Financial Highlights
Over the last trailing twelve months QURE reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS increased by 11.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.47% | ||
| ROE | -102.8% | ||
| Debt/Equity | 2.26 |
QURE Forecast & Estimates
20 analysts have analysed QURE and the average price target is 58.88 USD. This implies a price increase of 114.04% is expected in the next year compared to the current price of 27.51.
For the next year, analysts expect an EPS growth of 30.16% and a revenue growth -54.34% for QURE